secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001193125-26-092465
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology Q4 2025 net loss $81M; KOMZIFTI launch revenue $2.1M in first 5 weeks
--------------------------------------------------------------------------------

- Net loss of $81.0M in Q4 2025 vs $19.2M a year ago; full-year net loss $219.4M.
- Net product revenue $2.1M from KOMZIFTI in first five weeks of commercial sales post Nov 13 FDA approval.
- Collaboration revenue $15.2M (Kyowa Kirin milestones); R&D $64.4M, SG&A $39.1M.
- Cash and investments $667.2M; plus $180M in anticipated Kyowa Kirin payments expected to fund through KOMET-017 Phase 3 topline (2028).
- 2026 milestones include updated KOMET-007 data, KOMET-015 enrollment in GIST, and darlifarnib data in KRAS G12C tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526092465/0001193125-26-092465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526092465/kura-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-092465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer